Oliver Rolf Baumann Purchases 50,000 Shares of Veraxa Biotech (NASDAQ:VRXA) Stock

Posted by Patrick Bannon on Aug 31st, 2026

Veraxa Biotech Holding AG (NASDAQ:VRXA – Get Free Report) Director Oliver Rolf Baumann acquired 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average price of $1.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director directly owned 5,773,618 shares of the company’s stock, valued at $8,660,427. The trade was a 0.87% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Veraxa Biotech Price Performance

VRXA stock traded up $1.35 during midday trading on Monday, hitting $1.35. 290,790 shares of the company’s stock were exchanged, compared to its average volume of 552,024. Veraxa Biotech Holding AG has a 1-year low of $1.32 and a 1-year high of $27.36.

About Veraxa Biotech

(Get Free Report)

Veraxa Biotech AG is a biotechnology company focused on developing targeted antibody-based medicines, with an emphasis on antibody-drug conjugates (ADCs). These therapies are designed to use antibodies to identify specific cells and deliver therapeutic agents more selectively.

The company’s work includes antibody discovery, therapeutic development and the design of ADC candidates that combine targeting antibodies with drug payloads. Its research is directed primarily toward potential treatments for cancer and other serious diseases, although specific development programs and product approvals may change as its pipeline advances.

Publicly available information about Veraxa Biotech’s corporate history, geographic operations and leadership is limited.